Patent · US Active

Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same

US7635767B2 · kind B2 · utility

12Cited by
9References
46Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 26, 2009
Grant dateDec 22, 2009
Priority date
Expiry dateJan 26, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.